Effects of chr8 gain on OS. (A) Fusion status and risk stratification are significant for OS. (B) Gains in chr8 are associated with improved OS in fusion-negative cases. (C) No statistically significant association with gains in chr8 in fusion-positive cases. (D) OS similar regardless of the presence or absence of RAS pathway gene mutation. Chr, chromosome; FN, fusion-negative; FP, fusion-positive; OS, overall survival; RMS, rhabdomyosarcoma.